The pituitary-specific transcription factor, Pit-1, is necessary to mediate protein kinase A (PKA) regulation of the GH, PRL, and TSH-␤ subunit genes in the pituitary. Since these target genes lack classical cAMP DNA response elements (CREs), the mechanism of this regulation was previously unknown. We show that CREB binding protein ( 
INTRODUCTION
Pit-1 is a member of a family (POU) of transcription factors, and when bound to DNA, activates GH, Pit-1, PRL, and TSH-␤ subunit gene expression (1) (2) (3) (4) (5) (6) (7) (8) (9) . In addition to activating basal expression, Pit-1 is also necessary for cellular regulation of these target genes by hypothalamic hormones such as GHRH, TRH, and dopamine in a process requiring Pit-1 (8, (10) (11) (12) (13) (14) . In the anterior pituitary, the GHRH receptor is known to activate (15) , while the dopamine receptor is known to inhibit the cAMP/protein kinase A pathway (16) ; the TRH receptor is known to activate phospholipase C, leading to calcium mobilization and protein kinase C (PKC) activation (17) . Interestingly, GH, PRL, and TSH-␤ subunit genes do not contain consensus cAMP response elements (CREs) or AP-1 sites; instead, Pit-1 DNA response elements mediate induction by these pathways through a previously unknown mechanism.
On genes containing CREs, CREB binds as a homodimer and, after phosphorylation by protein kinase A (PKA), binds to CREB-binding protein (CBP) and a closely related coactivator (P300) (18) (19) (20) (21) (22) (23) . CBP, via an N-terminal domain, binds to CREB and functions to increase transcription through a more C-terminal domain, which is proposed to both activate histone acetyltransferase (24) and displace nucleosomes as well as recruit RNA polymerase II to the transcription complex (25) (26) (27) . The possibility that CBP could function independently of its recruitment to the transcription complex was recently suggested (28) .
RESULTS
Since CBP is known to integrate a number of diverse cell-signaling pathways (29) , we wanted to determine whether CBP acts as a cofactor for Pit-1-dependent gene regulation within the anterior pituitary. A cotransfection assay of the proximal PRL promoter reporter in a Pit-1-deficient cell line (CV-1) was performed to test this hypothesis. To activate the PKA pathway, a protein kinase A expression vector (30) was used; and to activate the PKC pathway, phorbol ester (TPA) treatment or a reconstituted TRH-signaling pathway was employed (31) . The proximal PRL promoter contains four well defined Pit-1 DNA-binding sites (10) . In this cell line, basal expression of the reporter construct was low but measurable. CBP or Pit-1 transfection activated this construct to a small extent after stimulation by these mediators (Fig. 1A) . However, the com-bination of both CBP and Pit-1 expression vectors synergistically activated the proximal PRL reporter in the presence of PKA, TPA, or TRH receptor and TRH. Treatment of transfected cells with a cAMP analog (8-Br-cAMP) elicted similar responses (data not shown). These responses clearly required Pit-1 DNAbinding, as a Pit-1 DNA-binding mutant (W261C, Ref. 32) was completely defective in this assay (Fig. 1A ). An intact Pit-1 N terminus was also necessary as the isoform Pit-1a (also referred to as Pit-1␤ or GHF-2), which contains a 26-amino acid (aa) insertion in the N terminus and is defective in activating pituitary gene expression in vitro (33) (34) (35) , was without stimulatory effect (Fig. 1A) . A mutant PKA expression vector or TRH treatment in the absence of cotransfected TRH receptor did not activate this promoter after CBP and Pit-1 cotransfection (data not shown). These PKA, TPA, and TRH responses with cotransfected Pit-1 and CBP were not observed on a control promoter (TK, Fig. 1B ). These data indicate that CBP functions as a Pit-1 cofactor to mediate PKA, TPA, and TRH induction of the PRL gene.
Since CBP significantly and specifically activated the proximal PRL reporter in a Pit-1-dependent manner, the ability of Pit-1 to bind to CBP was next evaluated. Figure 2A is a glutathione S-transferase (GST) pull-down assay using CBP fragments fused in-frame and C-terminal to GST. In data not shown, the quality and quantity of each GST-protein was determined on SDS-PAGE to ensure equivalence of the preparations. As can be seen, 35 S-labeled Pit-1 bound specifically to two regions of CBP (aa 118-737 and aa 1677-2441). As shown in Fig. 2B , 35 S-labeled Pit-1, regardless of PKA treatment, bound to the C/H1 (aa 362-429) and C/H3 (aa 1676-1844) domains of CBP but not to either GST alone or GST-CREB-binding domain (aa 463-661). In contrast, 35 S-labeled CREB bound only to the CREB domain and only after in vitro phosphorylation by the catalytic subunit of PKA. These data indicate that Pit-1 can bind specifically to CBP in vitro.
To prove that Pit-1 and CBP interact in pituitary cells, a GST pull-down assay using CBP aa 118-737 was performed, followed by a Western blot analysis for Pit-1 immunoreactivity. Figure 2C demonstrates that GST-CBP, but not GST alone, interacted equally well with Pit-1 from a rat pituitary cell line (GH 3 ), expressing both GH and PRL, before or after treatment with either 8-Br-cAMP, or TRH. The converse experiment followed by a Western blot analysis for CBP immunoreactivity showed that GST-Pit-1, but not GST alone, interacted equally well with CBP from the same pituitary cell line, before or after treatment with either 8-Br-cAMP, or TRH (Fig. 2D) . Finally, whole-cell extract (WCE) from untreated, 8-Br-cAMP-, or TRHtreated GH 3 cells was immunoprecipitated with a CBP antibody followed by a Western blot analysis of the immunoprecipitate for Pit-1 immunoreactivity (Fig. 2E) . CBP antiserum coimmunoprecipitated Pit-1, indicating that Pit-1 and CBP interact in vivo in pituitary cells.
Given that CBP and Pit-1 markedly activated the proximal PRL reporter in response to PKA, TPA, or TRH treatment and that CBP binds to Pit-1, we next determined what domains of CBP were responsible for this effect. In Fig. 3A , CBP deletion mutants were compared with wild-type (wt) CBP in a cotransfection assay in CV-1 cells. The ⌬ 8-1457 construct, which lacks the entire N-terminal half of CBP, was completely sufficient in mediating PKA stimulation of the proximal PRL reporter but was unable to mediate a normal TRH response. In contrast, the 1-1334 construct was defective in mediating a PKA effect but sufficient in mediating a TRH effect. The former result was expected since the known transactivation domain of CBP, contained within the carboxy terminus of CBP, was deleted in this construct. The latter result proves that the 1-1334 construct is functional and indicates that the TRH signaling pathway utilizes a different CBP domain, located in the N-terminal half of the molecule, to mediate transactivation. Finally the 1-450 construct, which lacks the CREB-binding site but contains the C/H1 domain, was fully sufficient to mediate the TRH response, indicating that the trans- CV-1 cells were transfected with a SV-40 expression vector (pSG5) containing either CBP or Pit-1 (wt, Pit-1a, or W261C) and a RSV expression vector containing either a wt PKA catalytic subunit cDNA or a mouse TRH receptor cDNA in the presence of either (A) the bovine PRL promoter (Prl) or (B) the thymidine kinase promoter (TK) fused upstream of a luciferase reporter gene. These are representative experiments (one of four) performed in triplicate, and data are shown as mean Ϯ SE. Fold basal activity is determined relative to cotransfection of the reporter construct with "empty" pSG5 and RSV expression vectors.
Fig. 2. Protein Interactions between CBP and Pit-1
A, GST pull-down assay of radiolabeled Pit-1 and fragments of the CBP protein. GST-CBP fusions proteins were synthesized, purified, and exposed to either 35 S-labeled Pit-1 or unprogrammed 35 S-labeled lysate (C). After extensive washing, proteins trapped by the resin were resolved on SDS-PAGE and detected by autoradiography. B, GST pull-down assay of radiolabeled Pit-1 or CREB, before or after in vitro phosphorylation with the catalytic subunit of PKA (PKA cat.) and fragments of the CBP protein.
GST-CBP proteins were synthesized as in panel A. C/H1 contains aa 1-450 of CBP, CREB contains aa 450-720, and C/H3 contains aa 1676-1891. C, GST pull-down assay of Pit-1 from GH 3 cells using GST-CBP protein. GST alone or GST-CBP, containing aa 118-737 of CBP, was exposed to WCE before (C) or after treatment with 8-Br-cAMP or TRH. After extensive washing, proteins were eluted from the resin and resolved by SDS-PAGE, and Western blot for Pit-1 was performed. WCE without exposure to GST resin demonstrates the 33-kDa Pit-1 protein (arrow). D, GST pull-down assay of CBP from GH 3 cells using a GST-Pit-1 protein. GST alone or GST-Pit-1, containing full-length rat Pit-1, was exposed to whole cell extract before or after treatment with 8-Br-cAMP or TRH. After extensive washing, proteins were eluted from the resin and resolved by SDS-PAGE, and Western blot analysis for CBP was performed. WCE without exposure to GST resin demonstrates the ϳ270-kDa CBP protein (arrow). E, Coimmunoprecipitation of CBP and Pit-1 from intact GH 3 cells. Whole cell extract was immunoprecipitated with an anti-CBP or a control (anti-GST) polyclonal rabbit antibody followed by a Western blot analysis for Pit-1. The arrow marks the location of Pit-1 coimmunoprecipitated with CBP. activation domain for this pathway is located in this amino-terminal region of CBP. In data not shown, treatment with a cAMP analog (8-Br-cAMP) or TPA produced a response pattern similar to PKA or TRH stimulation, respectively.
In Fig. 3B , a Western blot of cellular lysate from CV-1 cells transfected with these same constructs and probed with an antibody directed at either the amino or carboxy terminus of CBP. In data not shown, nuclear localization of each of these proteins was confirmed using enhanced green fluorescent proteintagged CBP deletion constructs. Note that CBP deletion constructs are expressed at similar levels in transfected CV-1 cells so that differences in protein expression of these constructs can not explain the results displayed in Fig. 3A .
Since the CREB binding domain of CBP is not required for the PKA response of the PRL gene, we next wanted to determine whether CREB was required for this response. Transfections were repeated using a human common glycoprotein ␣-subunit reporter gene construct, which contains two well defined CREs (36) (Fig. 4A) . CBP, but not Pit-1, markedly enhanced the PKA induction of this reporter vs. transfection of empty vector alone. Since CV-1 cells are relatively deficient in CBP vs. GH 3 cells (compare Fig. 3B with Fig. 2D ) and CBP cotransfection markedly increased CBP levels in CV-1 cells (compare lanes 1 and 2, Fig. 3B ), this result cAMP Regulation of Gene Expression by CBPwas expected. Cotransfection of an expression vector containing a mutation of the PKA phosphorylation site of CREB (CREBm, S133A, Ref. 37) completely blocked both the PKA response of the common glycoprotein ␣-subunit reporter in the absence (data not shown) and in the presence of CBP cotransfection (Fig. 4A ). Cotransfection of CREBm had no significant effect on PKA induction of the PRL reporter (Fig. 4B) . Cotransfection of wt CREB had no effect on induction of either reporter (Fig. 4, A and B) . Since CV-1 cells are not deficient in CREB, it is not surprising that wt CREB cotransfection did not augment the PKA response. We next tested whether known PKA sites on Pit-1 mediated the PKA effect seen on the PRL gene. However, mutation of all three PKA phosphorylation sites on Pit-1 (aa 115, 219, 220, Ref. 38) had no significant effect on PKA induction of the PRL gene (data not shown).
To determine what C-terminal region of CBP was sufficient for the PKA response, CBP fragments were fused downstream and in-frame of the GAL4 DNAbinding domain. Figure 5A demonstrates that GAL4-CBP constructs containing either aa 1677-2441 or aa 1891-2441 were sufficient to mediate a robust PKA response when tested on a UAS-thymidine kinase (TK) reporter, and these responses were similar to those observed on the PRL gene (Fig. 5B) . The isolated C/H3 domain (aa 1677-1891) mediated only a small PKA response. Mutation of the one consensus PKA site in CBP (S1772A) in the context of either the 1677-2441 or 1677-1891 construct had no effect on PKA induction, indicating that phosphorylation at this site is not important for this effect. As shown in Fig. 5B , only the 1677-2441 construct was active on the PRL reporter, whereas the 1891-2441 and 1677-1891 constructs were not active. Note also that the 1677-2441 construct alone was inactive on the PRL reporter and required cotransfection of Pit-1 to mediate a PKA effect. These data indicate that the C/H3 domain, which binds Pit-1, is required for the synergistic activation of the PRL reporter (compare aa 1677-2441 to aa 1891 to 2441) but was not active in isolation (aa 1677-1891). On a CRE reporter (four copies of a CRE upstream of the TK promoter), these constructs were all defective as compared with wt CBP in activating this reporter after PKA transfection (Fig. 5C ).
DISCUSSION
This study suggests a general mechanism for cAMP regulation of genes without CREs whereby CBP, bound constitutively to a cell-specific transcription factor directly or via additional cofactor interactions, stimulates gene expression. A CBP construct containing aa 1677-2441 is sufficient to mediate the PKA induction. Pit-1 presumably recruits this CBP fragment to the transcription complex by binding to aa 1677-1891, and subsequently aa 1891-2441 mediate the PKA induction. Interestingly, although this fragment does not contain intrinsic histone acetyltransferase (HAT) activity, it could recruit other cofactors such as p/CAF or p/CIP with known HAT domains.
Our data do not support a role for CBP phosphorylation in this process as mutation of the only consensus PKA site (S1772A) in this C-terminal fragment did not affect PKA induction; these data are in contrast to a recent paper by Xu et al. (39) . However, it is possible that another unknown PKA phosphorylation site in the C terminus of CBP could mediate this effect. Alternatively, PKA may phosphorylate other cofactors facilitating their recruitment to the C terminus of CBP. Experiments are in progress to test this hypothesis.
In contrast to the PKA effect, TRH stimulation of the PRL gene requires an N-terminal region of CBP (aa 1-450). Again, like the PKA effect, this CBP fragment is without intrinsic HAT activity, but other cofactors such as p/CAF could also be recruited to this fragment. Xu et al. also suggested that this same region of CBP could mediate induction by another growth factor (insulin) on a Pit-1 response element. Thus, CBP acts as a transcriptional cofactor for Pit-1 to permit regulation of the PRL gene by TRH-, TPA-, and PKA- In some transfections, a pSG5 expression vector containing either a wt CREB or CREB mutant cDNA (S133A, CREBm) was also included. Data are shown as mean Ϯ SE of two independent experiments each performed in triplicate. Fold basal activity is determined relative to cotransfection of the reporter construct with empty pSG5 expression vector. signaling pathways. As other genes in the pituitary are regulated by Pit-1, including GH, TSH-␤ subunit, and Pit-1 genes, CBP may subserve a similar function on these genes.
MATERIALS AND METHODS

Transfection Constructs
Luciferase reporter constructs contain either 1000 bp of 5Ј-flanking DNA of the bovine PRL promoter, 109 bp of 5Ј-flanking DNA of the herpes simplex TK promoter (minimal TK construct), 846 bp of 5Ј-flanking DNA of the human common glycoprotein ␣-subunit promoter (glycoprotein ␣-subunit), five copies of the GAL4 DNA-binding site upstream of TK (UAS-TK), or four copies of a consensus CRE upstream of TK. All Pit-1, CBP, and CREB constructs were in the SV40 expression construct, pSG5. Pit-1a and W261C were modifications of the original wt Pit-1 cDNA and therefore contained the same translation initiation site. CBP deletion mutant were made using restriction enzyme digestion and removal of wt mouse CBP domains as indicated: ⌬ 8-1457, RsrII; 1-1334, BstXI; ⌬142-705, ApaI; and 1-450, EcoRI. The reading frame and orientation of each mutant were confirmed in pSG5 by DNA sequencing.
Transfection Assays
In a 24-well format, 0.8 g of reporter with 1 g of pSG5 and/or 1 g of rous sarcoma virus (RSV) expression vectors were transfected per plate; 16 h after transfection, cultures were treated with serum-free medium for 8 h. For TRH stimulation, 50 nM TRH was added to the medium. All transfections were balanced for the same amount of expression vector using empty vector as needed. For analysis of the expression of transfected CBP constructs, CBP expression vectors were transfected as above, and a Western blot of total cellular lysate was performed using a CBP antibody that recognizes the extreme N terminus (aa 2-22, Santa Cruz Biotechnology, Santa Cruz, CA) or C terminus (aa 1736-2179, Upstate Biotechnology, Lake Placid, NY) of CBP.
GST and Immunoprecipitation Assays
Regions of the CBP protein were fused in-frame with GST in the pGEX4T2 vector (Pharmacia Biotech, Piscataway, NJ). Recombinant proteins were synthesized in JM109 bacteria and purified on glutathione-Sepharose resin under nondenaturing conditions. GST proteins were analyzed on SDS-PAGE before use in the assay to ensure equivalence of preparations. 35 S-labeled Pit-1 or CREB was generated in an in vitro transcription/translation system (TNT, Promega Biotech, Madison, WI) and exposed to the indicated GST protein. A, GAL4-CBP fusion proteins as indicated without and with Pit-1 were transfected in CV-1 cells, and PKA induction for 30 min at 37 C before exposure to the GST protein. After extensive washing with NET (150 mM NaCl, 1 mM EDTA, 0.5% NP40) at 4 C, the proteins trapped by the resin were resolved on SDS-PAGE and detected by autoradiography.
GST alone or GST-CBP, containing aa 118-737 of CBP, was exposed to whole cell GH 3 extract (WCE) made from individual 100-mm dishes before or after 10 min of treatment with 1 mM 8-Br-cAMP or 50 nM TRH. After extensive washing with NET at 4 C, proteins were eluted from the resin and resolved by SDS-PAGE, and Western blot analysis was performed with a mouse monoclonal anti-Pit-1 antibody made against the full-length rat Pit-1 molecule (Transduction Laboratories, Lexington, KY). GST alone or GST-Pit-1, containing full-length rat Pit-1, was exposed to whole-cell GH 3 extract made from individual 100-mm dishes before or after 10 min of treatment with 1 mM 8-Br-cAMP or 50 nM TRH. After extensive washing with NET at 4 C, proteins were eluted from the resin and resolved by SDS-PAGE, and Western blot analysis was performed with a rabbit polyclonal anti-CBP antibody made against aa 1736-2179 of mouse CBP (Upstate Biotechnology).
Whole-cell GH 3 extracts from 100-mm plates untreated or treated with either 8-Br-cAMP or TRH were immunoprecipitated with an anti-CBP or a control GST polyclonal rabbit antibody (anti-GST) and protein A/G resin. After extensive washing in NET and PBS, a Western blot analysis for Pit-1 using the monoclonal Pit-1 antibody described above was performed.
